Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX- 31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Exhibit 99.1 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update next phase of growth. This includes advancing VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep, into the clinic in mid-2026." Key First Quarter and Recent Highlights Topline Safety, Tolerability and Immunogen ...